GENETIC AND CLINICAL RISK FACTORS FOR HUMAN SLE NEPHRITIS
人类系统性红斑狼疮肾炎的遗传和临床危险因素
基本信息
- 批准号:7625430
- 负责人:
- 金额:$ 0.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-04-23 至 2007-11-30
- 项目状态:已结题
- 来源:
- 关键词:Antigen-Antibody ComplexBiopsyClinicalCollaborationsComputer Retrieval of Information on Scientific Projects DatabaseDefectDiseaseEventFundingGeneticGenetic PolymorphismGenetic screening methodGonadal Steroid HormonesGrantHumanImmunologicsImmunosuppressionInfectionInflammationInstitutionKidneyMeasuresMediatingMolecular GeneticsNephritisParentsPatientsProspective StudiesProteinsRecurrent diseaseRelapseResearchResearch DesignResearch PersonnelResourcesRisk FactorsSeveritiesSeverity of illnessSiblingsSourceStressSusceptibility GeneSystemic Lupus ErythematosusTestingTherapeutic immunosuppressionTimeUltraviolet RaysUnited States National Institutes of Healthchemokineconceptfollow-upgenetic analysistooltransmission process
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Nephritis is a frequent and severe manifestation of human SLE. Long-term immunosuppression is usually necessary. Relapse is common. SLE nephritis is the result of glomerular accumulation of immune complexes (IC). The risk factors for renal involvement, as well as the determinants of relapse and severity, are poorly understood. We postulate that 1) The dominant mechanism for glomerular IC accumulation is genetic and/or acquired defects of IC clearance proteins. Furthermore, the concurrence of 2 or more defective/deficient IC clearance proteins predisposes to severe nephritis. 2) IC mediate renal inflammation by regulating the local expression of chemotactic cytokines (chemokines). 3) Specific, quantifiable clinical events are triggers for SLE nephritis relapse, and influence disease severity. These hypotheses will be tested by 4 interrelated projects. Projects 1 and 2 analyze genetic polymorphisms of key IC clearance proteins (C2, C4, CR1,FcgRIIa, and FcgRIIIa), to determine which are susceptibility genes for human SLE nephritis. Project 3 examines genetic, molecular, and cellular mechanisms that regulate chemokine activity in human SLE nephritis. The genetic testing of Projects 1, 2, and 3 will involve 250 SLE nephritis patients (biopsy proven), 250 SLE patients who have never had nephritis, and 250 matched normals. Parents and siblings of the SLE patients will also be used for transmission disequilibrium testing (TDT). Project 4 is a meticulous, prospective study designed to determine the relationship between SLE relapse and genetic, immunologic, and clinical parameters. One hundred SLE patients with relapsing disease (50 with and 50 without renal manifestations) will be studied longitudinally over 5 years. In collaboration with Projects 1-3, serial quantitative measures of IC clearance proteins, chemokines, and specific clinical factors (stress, sex hormones, infection, UV radiation) will be obtained before, during, and after each of the more than 300 SLE relapses expected during follow-up. These variables will be correlated to disease activity and severity to determine which are "triggers" for SLE relapse, and which are determinants of the renal manifestations of SLE. From this analysis should emerge, for the first time, a clear picture of the risk factors for SLE nephritis and its relapse in humans. Summary: Concepts fundamental to understanding the genetic and clinical risk factors for human SLE nephritis should be revealed, thus providing tools for predicting SLE nephritis relapse and severity, and strategies for its management
这个子项目是众多研究子项目之一
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LEE A. HEBERT其他文献
LEE A. HEBERT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LEE A. HEBERT', 18)}}的其他基金
GENETIC AND CLINICAL RISK FACTORS FOR HUMAN SLE NEPHRITIS
人类系统性红斑狼疮肾炎的遗传和临床危险因素
- 批准号:
7718613 - 财政年份:2007
- 资助金额:
$ 0.31万 - 项目类别:
GENETIC AND CLINICAL RISK FACTORS FOR HUMAN SLE NEPHRITIS
人类系统性红斑狼疮肾炎的遗传和临床危险因素
- 批准号:
7374573 - 财政年份:2005
- 资助金额:
$ 0.31万 - 项目类别:
GENETIC AND CLINICAL RISK FACTORS FOR HUMAN SLE NEPHRITIS
人类系统性红斑狼疮肾炎的遗传和临床危险因素
- 批准号:
7198622 - 财政年份:2004
- 资助金额:
$ 0.31万 - 项目类别:
相似海外基金
A SIOPEN pragmatic clinical trial to MOnitor NeuroblastomA relapse with LIquid biopsy Sensitive Analysis (MONALISA)
SIOPEN 通过液体活检敏感性分析 (MONALISA) 监测神经母细胞瘤复发的实用临床试验
- 批准号:
10110442 - 财政年份:2024
- 资助金额:
$ 0.31万 - 项目类别:
EU-Funded
MONALISA: A SIOPEN pragmatic clinical trial to MOnitor NeuroblastomA relapse with LIquid biopsy Sensitive Analysis
MONALISA:一项 SIOPEN 实用临床试验,通过液体活检监测神经母细胞瘤复发 敏感性分析
- 批准号:
10103126 - 财政年份:2024
- 资助金额:
$ 0.31万 - 项目类别:
EU-Funded
PROJECT 3: Applying Liquid Biopsy Technologies to Detect Clinical Response and Mechanisms of Resistance in the Treatment of LMS
项目 3:应用液体活检技术检测 LMS 治疗的临床反应和耐药机制
- 批准号:
10493631 - 财政年份:2022
- 资助金额:
$ 0.31万 - 项目类别:
PROJECT 3: Applying Liquid Biopsy Technologies to Detect Clinical Response and Mechanisms of Resistance in the Treatment of LMS
项目 3:应用液体活检技术检测 LMS 治疗的临床反应和耐药机制
- 批准号:
10705742 - 财政年份:2022
- 资助金额:
$ 0.31万 - 项目类别:
Establishing the clinical utility of cell-free tumor DNA methylation profiling as a reliable liquid biopsy approach in brain tumors
建立无细胞肿瘤 DNA 甲基化分析作为脑肿瘤可靠液体活检方法的临床实用性
- 批准号:
10280279 - 财政年份:2022
- 资助金额:
$ 0.31万 - 项目类别:
Establishing the clinical utility of cell-free tumor DNA methylation profiling as a reliable liquid biopsy approach in brain tumors
建立无细胞肿瘤 DNA 甲基化分析作为脑肿瘤可靠液体活检方法的临床实用性
- 批准号:
10594945 - 财政年份:2022
- 资助金额:
$ 0.31万 - 项目类别:
Establishment and clinical application of CSF liquid biopsy using long-read next-generation sequencer.
长读长新一代测序仪脑脊液液体活检的建立及临床应用
- 批准号:
22K09227 - 财政年份:2022
- 资助金额:
$ 0.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The clinical application of liquid biopsy and its utility for the analysis of molecular mechanisms of the development and drug resistance of gestational trophoblastic disease.
液体活检的临床应用及其在妊娠滋养细胞疾病发生和耐药的分子机制分析中的应用。
- 批准号:
22H03220 - 财政年份:2022
- 资助金额:
$ 0.31万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Influence of intra-individual variability in serial screening samples on clinical decision-making for risk stratification and biopsy by a single PSA and additional markers
通过单一 PSA 和其他标志物进行的系列筛查样本中个体内变异性对风险分层和活检临床决策的影响
- 批准号:
10468509 - 财政年份:2022
- 资助金额:
$ 0.31万 - 项目类别:
Influence of intra-individual variability in serial screening samples on clinical decision-making for risk stratification and biopsy by a single PSA and additional markers
通过单一 PSA 和其他标志物进行的系列筛查样本中个体内变异性对风险分层和活检临床决策的影响
- 批准号:
10708766 - 财政年份:2022
- 资助金额:
$ 0.31万 - 项目类别:














{{item.name}}会员




